Search

Bridgebio Pharma Inc

Gesloten

SectorGezondheidszorg

80.23 -2.99

Overzicht

Wijziging aandelenprijs

24u

Huidig

Min

79.85

Max

82.73

Belangrijke statistieken

By Trading Economics

Inkomsten

24M

-167M

Verkoop

40M

195M

EPS

-0.84

Winstmarge

-85.626

Werknemers

834

EBITDA

68M

-113M

Aanbevelingen

By TipRanks

Aanbevelingen

Strong Buy

12 Maanden Prognose

+29.92% upside

Dividenden

By Acuity

Volgende Winsten

4 aug 2026

Marktinformatie

By TradingEconomics

Marktkapitalisatie

2.9B

16B

Vorige openingsprijs

83.22

Vorige sluitingsprijs

80.23

Nieuwssentiment

By Acuity

42%

58%

133 / 342 Rangschikking in Healthcare

Bridgebio Pharma Inc Grafiek

Eerdere prestaties zijn geen betrouwbare indicator voor toekomstige resultaten.

Gerelateerd nieuws

16 jul 2026, 23:52 UTC

Social Media
News

Netflix Inc. shares fell in after-hours trading following Q2 results. Revenue of $12.56 billion missed expectations, and guidance for 2026 was narrowed lower.

16 jul 2026, 23:46 UTC

News

Paychex declared a quarterly dividend of $1.19 per share, payable August 28, contributing to positive sentiment as shares rise in after-market trading.

16 jul 2026, 23:46 UTC

ETF Constituents
News
Correlated Moves

Vanguard Growth ETF declines after-hours, impacted by Netflix's drop and broader Nasdaq 100 downturn amid rising inflation concerns and central bank comments.

16 jul 2026, 23:41 UTC

News
Correlated Moves

Lam Research Corp shares are lower in after-market trading amid a sector-wide selloff following TSMC's capital expenditure announcement and bearish sentiment from options traders.

16 jul 2026, 23:36 UTC

News

T-Mobile US Inc. experienced routine after-market trading with little change since Thursday's close, maintaining its focus on versatile mobile internet plans.

16 jul 2026, 23:31 UTC

News
Correlated Moves

Micron Technology shares declined in after-market trading amid negative sentiment in the tech sector and concerns over rising capital costs from TSMC.

16 jul 2026, 23:21 UTC

News
Social Media

PayPal Holdings Inc. shares are lower in after-market hours as its board deems a $53 billion takeover bid from Stripe inadequate amid broader market declines.

16 jul 2026, 23:16 UTC

Correlated Moves
News

Intuit Inc shares are lower in after-market trading following a class action lawsuit alleging overstated revenue growth and competitive advantages. Concerns about layoffs persist.

16 jul 2026, 23:16 UTC

News
Social Media

Alphabet Inc shares are higher in after-market trading, rebounding from earlier session lows. Concerns persist over delays in the rollout of its Gemini AI.

16 jul 2026, 23:06 UTC

News

United Airlines Holdings Inc shares are lower in after-market hours, reflecting broader market declines amid concerns over major tech stocks and geopolitical risks.

16 jul 2026, 23:02 UTC

News
Social Media

Intuitive Surgical shares fell in after-market trading despite strong earnings, as management cited U.S. market challenges and a Class II recall of surgical components.

16 jul 2026, 23:01 UTC

News

Escalating military tensions in the Middle East are impacting the United States Oil Fund LP, which is trading lower during after-market hours.

16 jul 2026, 23:01 UTC

News
ETF Constituents
Correlated Moves
Macro News

Vanguard Information Technology ETF declines after major indices drop, led by weakness in semiconductor stocks and a significant decline in Netflix shares.

16 jul 2026, 23:01 UTC

News

Fiserv Inc. shares are lower in after-market trading amid operational challenges, including a 2% revenue decline and a significant drop in operating income.

16 jul 2026, 20:07 UTC

News

Spot silver prices are higher today, despite earlier pulling back from a session high, amid escalating U.S.-Iran tensions and rising inflation concerns.

16 jul 2026, 20:07 UTC

News
Correlated Moves

CHF/HKD is trading lower as initial jobless claims fall to a two-month low, indicating labor market strength amid rising geopolitical tensions.

16 jul 2026, 20:06 UTC

News
Correlated Moves

Gold prices are lower as inflation risks rise amid the U.S.-Iran conflict. Earlier, gold peaked at $3,992.10 per ounce before declining.

16 jul 2026, 20:06 UTC

News
Correlated Moves

Spot silver prices are declining amid rising U.S.-Iran tensions and inflation concerns, currently trading around $56.82 per ounce. Gold also fell sharply today.

16 jul 2026, 20:06 UTC

Macro Event
Correlated Moves
News

Xcel Energy shares are higher, supported by analysts' positive ratings adjustments and a favorable move in the Electric Utilities sub-sector.

16 jul 2026, 20:06 UTC

Correlated Moves
News

Spot silver prices are lower today, trading around $56.82 per ounce amid rising inflation concerns and expectations for Federal Reserve rate hikes.

16 jul 2026, 20:06 UTC

News
Correlated Moves

Spot silver prices are declining amid rising U.S.-Iran tensions and inflation concerns. The metal is trading near $56.82 per ounce, reflecting broader weakness in precious metals.

16 jul 2026, 20:06 UTC

News
Correlated Moves

Spot silver prices are declining amid rising U.S.-Iran tensions and inflation concerns, trading around $56.82 per ounce after a significant drop since Wednesday.

16 jul 2026, 20:06 UTC

Correlated Moves
News

Spot silver prices are lower, trading around $56.82 per ounce amid rising U.S.-Iran tensions and inflation concerns. Gold also declined significantly today.

16 jul 2026, 20:06 UTC

Correlated Moves
News

Spot silver prices are lower today, trading around $56.82 per ounce amid rising inflation concerns and expectations for Federal Reserve rate hikes.

16 jul 2026, 20:06 UTC

Correlated Moves
News

GBP/HKD is trading lower amid the Bank of Korea's interest rate hike to 2.75%. The currency pair reached a session low following early gains.

16 jul 2026, 20:03 UTC

Correlated Moves
News

Wedbush initiated coverage on Verisign with an Outperform rating. Shares are gaining today, reflecting positive sentiment after closing at $268.85.

16 jul 2026, 20:03 UTC

News

O'Reilly Automotive advances amid speculation of a $10 billion acquisition of Genuine Parts' auto parts unit, with analysts citing potential benefits despite FTC review concerns.

16 jul 2026, 20:03 UTC

Correlated Moves
Social Media
News

Qualcomm Inc shares are lower as the semiconductor sector faces pressure from Micron Technology's supply agreements and a notable decline in the Nasdaq 100 Index.

16 jul 2026, 20:02 UTC

News

Align Technology Inc. reported first-quarter revenue of $1.00 billion, slightly above expectations, but shares are lower amid broader market unease and geopolitical tensions.

16 jul 2026, 19:56 UTC

News
Social Media

Expedia Group shares rise after Wedbush initiated coverage with an Outperform rating and a price target of $334, indicating growth potential.

Peer Vergelijking

Prijswijziging

Bridgebio Pharma Inc Prognose

Koersdoel

By TipRanks

29.92% opwaarts potentieel

12 Maanden Prognose

Gemiddelde 107.39 USD  29.92%

Hoogste 157 USD

Laagste 93 USD

Gebaseerd op 19 Wall Street-analisten die 12-maands prijsdoelen bieden voor Bridgebio Pharma Inc - Dist. in de afgelopen 3 maanden.

Beoordelingsconsensus

By TipRanks

Strong Buy

19 ratings

18

Buy

1

Hold

0

Sell

Sentiment

By Acuity

133 / 342 Rangschikking in Gezondheidszorg

Nieuwssentiment

Bullish Bewijs

Volatiliteit

Onder gemiddelde

Nieuws Volume (RCV)

Onder gemiddelde

Financieel

Verkoop- en administratiekosten

Bedrijfskosten

Winst voor belastingen

Verkoop

Kosten van verkopen

Brutowinst op verkopen

Rente-uitgaven op schulden

EBITDA

Operationele winst

$

Over Bridgebio Pharma Inc

BridgeBio Pharma, Inc., a commercial-stage biopharmaceutical company, discovers, creates, tests, and delivers transformative medicines to treat patients who suffer from genetic diseases and cancers. Its products in development programs include AG10, a next-generation oral small molecule near-complete TTR stabilizer that is in Phase 3 clinical trial for the treatment of TTR amyloidosis, or transthyretin amyloid cardiomyopathy (ATTR-CM); low-dose infigratinib, an oral FGFR1-3 selective tyrosine kinase inhibitor, which is in Phase 3 double-blinded, placebo-controlled pivotal study for the treatment option for children with achondroplasia; and BBP-631, an AAV5 gene transfer product candidate that is in Phase 1/2 clinical trial for the treatment of congenital adrenal hyperplasia, or CAH, driven by 21-hydroxylase deficiency, or 21OHD. The company also develops Encaleret, a small molecule antagonist of the calcium sensing receptor, or CaSR, which is in phase 3 clinical trial for treating autosomal dominant hypocalcemia type 1, or ADH1; and BBP-418, a glycosylation substrate pro-drug that is in Phase 3 clinical trial for treating limb-girdle muscular dystrophy type 2I/R9 (LGMD2I/R9). In addition, it engages in developing products for mendelian, oncology, and gene therapy diseases. BridgeBio Pharma, Inc. has license and collaboration agreements with the Leland Stanford Junior University; and Leidos Biomedical Research, Inc. The company was founded in 2015 and is headquartered in Palo Alto, California.
help-icon Live chat